During the last session, Capricor Therapeutics Inc (NASDAQ:CAPR)’s traded shares were 1.31 million, with the beta value of the company hitting 0.88. At the end of the trading day, the stock’s price was $10.09, reflecting an intraday loss of -5.26% or -$0.56. The 52-week high for the CAPR share is $23.40, that puts it down -131.91 from that peak though still a striking 65.11% gain since the share price plummeted to a 52-week low of $3.52. The company’s market capitalization is $461.19M, and the average intraday trading volume over the past 10 days was 2.46 million shares, and the average trade volume was 2.10 million shares over the past three months.
Capricor Therapeutics Inc (CAPR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CAPR has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.39.
Capricor Therapeutics Inc (NASDAQ:CAPR) trade information
Capricor Therapeutics Inc (CAPR) registered a -5.26% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.26% in intraday trading to $10.09, hitting a weekly high. The stock’s 5-day price performance is -9.26%, and it has moved by -19.67% in 30 days. Based on these gigs, the overall price performance for the year is 68.45%. The short interest in Capricor Therapeutics Inc (NASDAQ:CAPR) is 13.78 million shares and it means that shorts have 5.04 day(s) to cover.
The consensus price target of analysts on Wall Street is $15, which implies an increase of 32.73% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10 and $21.5 respectively. As a result, CAPR is trading at a discount of -113.08% off the target high and 0.89% off the low.
Capricor Therapeutics Inc (CAPR) estimates and forecasts
In the rating firms’ projections, revenue will increase 366.12% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 2.6M as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 44.55M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 3.97M and 2.26M respectively. In this case, analysts expect current quarter sales to shrink by -34.60% and then jump by 1,869.81% in the coming quarter.
CAPR Dividends
Capricor Therapeutics Inc is due to release its next quarterly earnings on 2025-May-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Capricor Therapeutics Inc (NASDAQ:CAPR)’s Major holders
Capricor Therapeutics Inc insiders own 16.80% of total outstanding shares while institutional holders control 40.47%, with the float percentage being 48.64%. BLACKROCK INC. is the largest shareholder of the company, while 171.0 institutions own stock in it. As of 2024-06-30, the company held over 1.63 million shares (or 5.1145% of all shares), a total value of $7.77 million in shares.
The next largest institutional holding, with 1.55 million shares, is of VANGUARD GROUP INC’s that is approximately 4.8645% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $7.39 million.
Also, the Mutual Funds coming in first place with the largest holdings of Capricor Therapeutics Inc (CAPR) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. Data provided on Mar 31, 2025 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 1.19 shares. This amounts to just over 2.61 percent of the company’s overall shares, with a $12.01 million market value. The same data shows that the other fund manager holds slightly less at 995.68, or about 2.18% of the stock, which is worth about $10.05 million.
